March 4, 2019 10:37 AM ESTUpdated March 5, 08:08 AM
People

Build­ing on mo­men­tum from pos­i­tive di­a­betes da­ta, Zaf­gen scoops Bio­gen alum Priya Sing­hal as head of R&D

Amber Tong

On the heels of some pos­i­tive mid-stage da­ta on its lead di­a­betes drug, Zaf­gen $ZFGN has brought in sea­soned biotech ex­ec Priya Sing­hal to steer­ing …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Up­dat­ed: Am­gen obe­si­ty shot shows 20% weight loss, but dos­ing ques­tions hang over read­out

Sarep­ta li­cens­es Ar­row­head­'s RNA-based rare dis­ease pipeline, promis­ing big biobucks

The Biden ad­min­is­tra­tion wants Medicare and Med­ic­aid to cov­er GLP-1s. Will the Trump White House al­low it?

Up­dat­ed: Roche buys out CAR-T part­ner Po­sei­da for $1B up­front

Food al­ler­gy biotech Al­ladapt clos­es af­ter Phase 3 talks with FDA

Soleno’s rare pe­di­atric dis­ease drug faces PDU­FA de­lay by three months

A service from the Financial Times